ArticleJournal of the National Cancer Institute2023

Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.

Minkyoung Yoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.